Detalhe da pesquisa
1.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246194
2.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
Future Oncol
; 20(15): 959-968, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38390818
3.
Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand.
Aust N Z J Obstet Gynaecol
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299485
4.
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours.
Br J Cancer
; 128(8): 1418-1428, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797356
5.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Br J Cancer
; 129(5): 797-810, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37474720
6.
Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study.
Support Care Cancer
; 31(5): 304, 2023 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37101013
7.
Skeletal muscle morphology in patients receiving primary versus interval cytoreductive surgery for advanced high-grade serous ovarian cancer.
Int J Gynecol Cancer
; 33(10): 1587-1594, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37220950
8.
Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
Br J Cancer
; 126(3): 401-408, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34373567
9.
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
Future Oncol
; 18(31): 3473-3480, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36047545
10.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Int J Gynecol Cancer
; 32(4): 560-565, 2022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551895
11.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305099
12.
Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.
Br J Cancer
; 122(7): 1059-1067, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037400
13.
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Oncologist
; 25(3): e520-e527, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162809
14.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Lancet Oncol
; 20(9): 1306-1315, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378459
15.
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Gynecol Oncol
; 154(2): 441-448, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118141
16.
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
BMC Cancer
; 18(1): 726, 2018 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29986670
17.
Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Int J Gynecol Cancer
; 27(4): 708-713, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28441251
18.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
Gynecol Oncol
; 161(1): 328-329, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33551198
19.
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].
Gynecol Oncol
; 157(2): 558-559, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087992
20.
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Thorax
; 69(10): 895-902, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25037982